Your browser doesn't support javascript.
loading
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Tannir, Nizar M; Signoretti, Sabina; Choueiri, Toni K; McDermott, David F; Motzer, Robert J; Flaifel, Abdallah; Pignon, Jean-Christophe; Ficial, Miriam; Frontera, Osvaldo Arén; George, Saby; Powles, Thomas; Donskov, Frede; Harrison, Michael R; Barthélémy, Philippe; Tykodi, Scott S; Kocsis, Judit; Ravaud, Alain; Rodriguez-Cid, Jeronimo R; Pal, Sumanta K; Murad, Andre M; Ishii, Yuko; Saggi, Shruti Shally; McHenry, M Brent; Rini, Brian I.
Affiliation
  • Tannir NM; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. ntannir@mdanderson.org.
  • Signoretti S; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Choueiri TK; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • McDermott DF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Motzer RJ; Division of Medical Oncology, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.
  • Flaifel A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Pignon JC; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Ficial M; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Frontera OA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • George S; Centro de Investigación Clínica Bradford Hill, Recoleta, Chile.
  • Powles T; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
  • Donskov F; Department of Urology, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, United Kingdom.
  • Harrison MR; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Barthélémy P; Department of Medicine, Duke Cancer Institute, Durham, North Carolina.
  • Tykodi SS; Medical Oncology Unit, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Kocsis J; Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Ravaud A; Oncology Department, Debrecen University Clinical Center, Debrecen, Hungary.
  • Rodriguez-Cid JR; Department of Oncoradiology, Bács-kiskun County Teaching Hospital (BKMK) Centre of Oncoradiology, Kecskemét, Hungary.
  • Pal SK; Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.
  • Murad AM; Centro Oncológico, Hospital Médica Sur, Mexico City, Mexico.
  • Ishii Y; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California.
  • Saggi SS; CENANTRON-PERSONAL-Precision Oncology, Belo Horizonte, Minas Gerais, Brazil.
  • McHenry MB; Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey.
  • Rini BI; Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey.
Clin Cancer Res ; 27(1): 78-86, 2021 01 01.
Article in En | MEDLINE | ID: mdl-32873572
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2021 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2021 Document type: Article Country of publication: